O T C
PAOG 2021 CBD Nutraceuticals Rollout Preview This Friday

  Sandusky, OH, May 5, 2021 – OTC PR WIRE — PAO Group, Inc. (USOTC: PAOG) today confirmed a CBD Nutraceutical Sales Rollout Presentation scheduled this Friday, May 7, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived

PAOG CBD Nutraceuticals To Hit Market This Year

  Sandusky, OH, May 4, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today confirmed plans to present the company’s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive

PAOG 2021 CBD Nutraceutical Sales Rollout Plan Presentation Scheduled This Friday

  Sandusky, OH, May 3, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today announced plans to present the company’s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive

PAOG Anticipates Boost To CBD Pharmaceutical Research Initiative From Improving Cannabis Legalization Outlook

  Sandusky, OH, April 28, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today highlighted recent cannabis legalization progress anticipated to enhance PAOG’s ongoing CBD Pharmaceutical Development Program. PAOG has partnered with Puration, Inc. (OTC Pink: PURA) to build a pharmaceutical grade indoor hemp grow facility and CBD extraction facility in

PAOG Announces Opportunity To Expand CBD Pharmaceutical Research

  Sandusky, OH, April 13, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today released a management update on the company’s ongoing CBD Pharmaceutical Development Program. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived

PAOG CBD Pharmaceutical Development Update Coming Tomorrow, Tuesday April 13, 2021

  Sandusky, OH, April 12, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today confirmed a management update on the company’s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is

PAOG Advances CBD Pharmaceutical Developments Backed By US Patent

  Sandusky, OH, April 8, 2021 – OTC PR WIRE —  PAO Group, Inc. (OTC Pink: PAOG) today announced a management update on the company’s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is

PAOG Targets September 2021 To Introduce CBD Nutraceuticals To Market Co-Packed By ALKM and Marketed Through USMJ

  Sandusky, OH, March 16, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today released details on the company’s nutraceutical developments initiative following last week’s introduction of adding CBD RELAX-RX to existing CBD RespRx developments.  The details today are highlighted by the company’s September 2021 go-to-market target date with nutraceutical co-packing

PAOG Announces RELAX-RX Nutraceutical For $18 Billion Anxiety And Depression Treatment Market

  Sandusky, OH, March 8, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today announced initiating the development of its new nutraceutical, RELAX-RX, targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The company recently announced plans to produce a variety of nutraceuticals

PAOG Plans To Add CBD Nutraceutical Revenue In 2021 To Cannabis Cultivation Revenue

  Sandusky, OH, February 10, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced the company plans to add revenue this year in 2021 from its developing CBD nutraceutical business to currently anticipated revenue from its cannabis cultivation business revenue. PAOG recently announced that it anticipated reporting approximately $50,000 in

Recent Posts

Recent Posts

Contact Us

All Rights Reserved © 2019